Spyre Therapeutics announces first patient dosed in Phase 3 SKYWAY trial

Spyre Therapeutic announced that the first patient has been dosed in its Phase 2 SKYWAY basket trial evaluating SPY072 in RA, PsA, and axSpA. “RA, PsA, and axSpA collectively affect millions of patients globally, including more than three million in the U.S., yet the vast majority do not achieve durable remission with today’s therapies and require frequent injections or infusions,” said Josh Friedman, M.D., Ph.D., SVP of Clinical Development at Spyre. “The evidence for TL1A inhibition in these conditions spans human genetics, in vitro studies, and animal models, suggesting that SPY072 has the potential to match or exceed the efficacy of current therapeutics. With a target dosing profile superior to any existing therapy in these indications, SPY072 has the potential to become a first- and best-in-class therapy for rheumatic diseases.”